

Phase I study of PM534 to patients with advanced solid tumors

Submission date 14/05/2026	Recruitment status Recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 20/05/2026	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 20/05/2026	Condition category Other	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date

Contact information

Type(s)

Public

Contact name

None Pharma Mar S.A. Clinical Development Oncology Unit

Contact details

Avenida De Los Reyes 1
Poligono Industrial La Mina
Colmenar Viejo, Madrid
Spain
28770
+34918466000
clinicaltrials@pharmamar.com

Type(s)

Scientific

Contact name

None Pharma Mar S.A. Clinical Development Oncology Unit

Contact details

Avenida De Los Reyes 1
Poligono Industrial La Mina
Colmenar Viejo, Madrid
Spain

28770
+34 918466000
clinicaltrials@pharmamar.com

Type(s)

Principal investigator

Contact name

Dr Martin Forster

Contact details

University College Hospital
250 Euston Road
London
Spain
NW1 2PG
+44 2034479091
m.forster@ucl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

2024-519013-57-00

Integrated Research Application System (IRAS)

1011534

Protocol number

PM534-A-002-24

Study information

Scientific Title

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Acronym

PM534A2

Study objectives

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 22/10/2025, East of England - Cambridgeshire and Hertfordshire (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 020 7104 8096; cambsandherts.rec@hra.nhs.uk), ref: 25/EE/0192

Primary study design

Interventional

Allocation

N/A: single arm study

Masking

Open (masking not used)

Control

Uncontrolled

Assignment

Single

Purpose

To identify the dose-limiting toxicities (DLTs), and to determine the maximum tolerated dose (MTD) and the recommended dose (RD) and to evaluate the antitumor activity in solid tumors

Study type(s)**Health condition(s) or problem(s) studied**

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Interventions

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Primary outcome(s)

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Key secondary outcome(s)**Completion date**

08/08/2028

Eligibility

Key inclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

Date of first enrolment

10/04/2026

Date of final enrolment

30/07/2027

Locations

Countries of recruitment

United Kingdom

England

Spain

Study participating centre

University College London Hospitals NHS Foundation Trust

250 Euston Road

London
England
NW1 2PG

Sponsor information

Organisation

PharmaMar (Spain)

ROR

<https://ror.org/02h694m69>

Funder(s)

Funder type

Funder Name

PharmaMar

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Spain

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available